The most important findings of the current study are as follows: (i) intravenous P2Y12 inhibition with cangrelor is used in a small proportion of patients undergoing invasive cardiac procedures, (ii) patients receiving cangrelor are generally high-risk patients (including patients after cardiac arrest, on mechanical ventilation and/or in cardiogenic shock), and (iii) patients receiving cangrelor had low rates of stent thrombosis and acceptable bleeding rates, given their high-risk profile. Here, P2RY12 is linked to Shock.